Balli Şevket, Kanlioğlu Pınar, Altin Hüsnü F
Department of Pediatric Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training & Research Hospital, University of Health Sciences, İstanbul, Turkey.
Department of Pediatric Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training & Research Hospital, University of Health Sciences, İstanbul, Turkey.
Cardiol Young. 2024 Apr;34(4):776-781. doi: 10.1017/S1047951123003487. Epub 2023 Oct 12.
In this study, we describe our experience utilising Advisor™ High Density (HD) Grid mapping catheter in transcatheter ablation of intraatrial re-entrant and focal atrial tachycardias with or without CHD.
Forty-five consecutive patients with intraatrial re-entrant and focal atrial tachycardia who underwent a transcatheter ablation procedure by using Advisor™ HD Grid mapping catheter and high-density mapping system in our hospital from January 2017 to January 2023 were included into the study.
The mean age of the patients was 14.2 ± 7.3 years (6-32 years), and the mean weight was 48.3 ± 16.2 kg (22-83 kg). Of the total 45 patients, 21 were intraatrial re-entrant tachycardia and 25 were focal atrial tachycardia. Of the 21 re-entrant circuits, 15 were classified as cavotricuspid isthmus-dependent and 5 were non-cavotricuspid isthmus-dependent. In one patient, two re-entrant circuits were identified. A transbaffle ablation was successfully performed from the left atrium in one patient. Of the 25 focal atrial tachycardia, 19 were from right atrium and 6 were from left atrium. A cryoablation was performed in only one patient and radiofrequency ablation in others. The mean procedure time was 180 ± 64 minutes. The mean follow-up period was 69.3 ± 35.3 months. Acute success was 95.5%. Recurrence was noted in two patients (4.4%).
Advisor™ HD Grid mapping catheter was found to be safe and achieved an acceptable success in transcatheter ablation of patients with intraatrial re-entrant tachycardia and focal atrial tachycardias.
在本研究中,我们描述了使用Advisor™高密度(HD)网格标测导管经导管消融有或无先天性心脏病(CHD)的房内折返性和局灶性房性心动过速的经验。
纳入2017年1月至2023年1月在我院使用Advisor™ HD网格标测导管和高密度标测系统接受经导管消融手术的45例连续的房内折返性和局灶性房性心动过速患者。
患者的平均年龄为14.2±7.3岁(6 - 32岁),平均体重为48.3±16.2千克(22 - 83千克)。45例患者中,21例为房内折返性心动过速,25例为局灶性房性心动过速。在21个折返环中,15个被分类为三尖瓣峡部依赖性,5个为非三尖瓣峡部依赖性。1例患者中识别出两个折返环。1例患者成功从左心房进行了跨瓣环消融。25例局灶性房性心动过速中,19例起源于右心房,6例起源于左心房。仅1例患者进行了冷冻消融,其他患者进行了射频消融。平均手术时间为180±64分钟。平均随访期为69.3±35.3个月。急性成功率为95.5%。2例患者(4.4%)出现复发。
发现Advisor™ HD网格标测导管在经导管消融房内折返性心动过速和局灶性房性心动过速患者中是安全的,并取得了可接受的成功率。